Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Silo Pharma beginnt wichtige Studie für PTSD-Behandlung | 1 | Investing.com Deutsch | ||
Mi | Silo Pharma, Inc.: Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment | 275 | GlobeNewswire (Europe) | Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental... ► Artikel lesen | |
07.03. | Silo Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
26.02. | Silo Pharma, Inc.: Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment | 462 | GlobeNewswire (Europe) | SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
18.02. | Silo Pharma, Inc.: Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment | 3 | GlobeNewswire (USA) | ||
11.02. | Silo Pharma reports positive early data on pain treatment implant | 4 | Investing.com | ||
11.02. | Silo Pharma meldet positive frühe Daten zu Schmerzbehandlungsimplantat | 9 | Investing.com Deutsch | ||
11.02. | Silo Pharma, Inc.: Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia | 153 | GlobeNewswire (Europe) | No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or... ► Artikel lesen | |
SILO PHARMA Aktie jetzt für 0€ handeln | |||||
22.01. | Silo Pharma reicht vorläufiges Patent für PTSD-Behandlung ein | 3 | Investing.com Deutsch | ||
22.01. | Silo Pharma files provisional patent for PTSD treatment | 3 | Investing.com | ||
22.01. | Silo Pharma, Inc.: Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment | 1 | GlobeNewswire (USA) | ||
08.01. | Silo Pharma Shares Are Surging Today: What's Going On? | 2 | Benzinga.com | ||
08.01. | Silo Pharma shares soar on patent allowance news | 1 | Investing.com | ||
08.01. | Silo Pharma secures patent for PTSD intranasal treatment | 2 | Investing.com | ||
08.01. | Silo Pharma erhält Patent für intranasale PTBS-Behandlung | 6 | Investing.com Deutsch | ||
02.01. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.01. | Silo Pharma progresses with PTSD and pain treatments | 2 | Investing.com | ||
02.01. | Silo Pharma macht Fortschritte bei PTBS- und Schmerzbehandlungen | - | Investing.com Deutsch | ||
02.01. | Silo Pharma, Inc.: Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain | 212 | GlobeNewswire (Europe) | IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025 (GLOBE... ► Artikel lesen | |
20.12.24 | Silo Pharma, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 82,45 | -5,12 % | Bayer, Vidac Pharma, BioNTech - Niederschläge und neue Maßstäbe | Glyphosat und kein Ende. Die Übernahme des US-amerikanischen Agrarunternehmens Monsanto durch Bayer im Jahr 2018 entwickelt sich weiterhin zum Milliardengrab, erneut entschied ein Gericht gegen die... ► Artikel lesen | |
CUREVAC | 2,612 | +1,16 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
AMGEN | 287,30 | -0,28 % | Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis | ||
NOVAVAX | 5,998 | +1,27 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
BIOGEN | 126,70 | +0,12 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
ILLUMINA | 73,55 | +0,25 % | Illumina Announces Board Changes: Scott Gottlieb Appointed Chair, Keith Meister Joins | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), an American biotechnology company, Tuesday has announced changes to its Board of Directors. Scott Gottlieb, MD, who has been a board member since... ► Artikel lesen | |
CRISPR THERAPEUTICS | 31,700 | -7,04 % | Crispr Therapeutics Aktie: Verliert ihren Kurs? | Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte... ► Artikel lesen | |
MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,420 | +0,40 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 6,596 | +0,67 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
EDITAS MEDICINE | 1,086 | +0,74 % | Zacks Research Comments on Editas Medicine FY2027 Earnings | ||
BIOCRYST PHARMACEUTICALS | 7,036 | +1,38 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 0,880 | -1,12 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | +2,15 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 59,80 | +1,36 % | Sarepta downgraded at RBC Capital on gene therapy concerns |